NCT05328115View on ClinicalTrials.gov

A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
Alzheimer DiseaseDementia AlzheimersDementia, Mild
Interventions
BIOLOGICAL

ALZ-101

Intramuscular injections of adjuvanted peptide vaccine against oligomeric Amyloid Beta.

OTHER

Placebo

Intramuscular injections of adjuvanted placebo.

Trial Locations (1)

FI-20520

Clinical Research Services Turku -CRST Oy, Turku

Sponsors

Lead Sponsor

Alzinova AB
All Listed Sponsors
collaborator

CRST Oy

INDUSTRY

lead

Alzinova AB

INDUSTRY

NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter